NewAmsterdam Pharma Posts $19.2M in Q3 Revenue
NAMS is trading near its 52-week low of $19.13 (5.8% above the low).
Summary
NewAmsterdam Pharma reported third-quarter revenue of $19.2M, its first top-line print since the European Commission approved Ubeslo and Evlarco in September. That approval is the launch engine behind the revenue line, so the number is the first read on how quickly the EU rollout is converting. The quarter's loss per share came in at 14c, and research and development expenses were $39.4M. The company is still burning cash — Q2's loss widened to $64.1M on higher R&D spend, against a $678M cash balance — so revenue scale matters less than the burn rate and any update to the funding runway. The headline carries no guidance and no year-over-year comparison, so the quarter's quality is unclear from this alone.
At the time of this announcement, NAMS was trading at $20.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $19.13 to $42.21. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.